Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Accumulated Expenses (2020 - 2025)

Mirum Pharmaceuticals has reported Accumulated Expenses over the past 6 years, most recently at $196.2 million for Q4 2025.

  • Quarterly results put Accumulated Expenses at $196.2 million for Q4 2025, up 75.27% from a year ago — trailing twelve months through Dec 2025 was $196.2 million (up 75.27% YoY), and the annual figure for FY2025 was $196.2 million, up 75.27%.
  • Accumulated Expenses for Q4 2025 was $196.2 million at Mirum Pharmaceuticals, up from $148.2 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for MIRM hit a ceiling of $196.2 million in Q4 2025 and a floor of $345000.0 in Q4 2021.
  • Median Accumulated Expenses over the past 5 years was $35.4 million (2021), compared with a mean of $59.6 million.
  • Biggest five-year swings in Accumulated Expenses: crashed 92.81% in 2021 and later skyrocketed 3798.27% in 2024.
  • Mirum Pharmaceuticals' Accumulated Expenses stood at $345000.0 in 2021, then soared by 611.88% to $2.5 million in 2022, then skyrocketed by 3098.05% to $78.5 million in 2023, then soared by 42.51% to $111.9 million in 2024, then skyrocketed by 75.27% to $196.2 million in 2025.
  • The last three reported values for Accumulated Expenses were $196.2 million (Q4 2025), $148.2 million (Q3 2025), and $127.1 million (Q2 2025) per Business Quant data.